Skip to content

Author

Armela Hasa

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Preoperative frailty and tumor volume as determinants of primary management strategy and outcomes in petroclival meningioma patients

Objective We aimed to study how patient frailty, pre-operative tumor volume, and symptom burden collectively impact primary management choice, postoperative complication rates, and outcomes in the treatment of petroclival meningiomas. Methods We retrospectively analyzed a cohort of 73 patients diagnosed with petroclival meningiomas at Emory Healthcare from 2000 to 2022. Frailty was quantified with the 5-item modified frailty index (mFI-5). Tumor volume was measured from pre-operative MRI with 3D Slicer. Tumor-related symptoms were clustered into five domains (visual, vestibulocochlear, sensory, motor, headache) and summed into a composite Symptom Burden Score (SBS). Primary management was categorized as surgical resection versus conservative therapy (serial imaging or radiotherapy). Multivariable logistic regression evaluated predictors of treatment selection; a second model examined 30-day postoperative complications in surgical patients. Linear mixed-effects models (LMM) tracked SBS, and domain-specific generalized linear mixed-effects models (GLMM) assessed symptom resolution at 3, 6, and 12 months, controlling for both frailty and treatment approach. Sensitivity analyses dichotomized frailty (mFI-5 = 0 vs. ≥1). Significance threshold: two-sided p < 0.05. Results Surgically treated tumors were larger than conservatively managed lesions (median 14.3 cm3 vs. 8.9 cm3; p = 0.018), and management choice varied by frailty strata (χ2 = 12.86, p = 0.015). In multivariable analysis, neither tumor volume (OR 1.04, 95% CI 0.97–1.11) nor mFI-5 score (OR 0.56, 95% CI 0.20–1.82) independently predicted operative selection. Thirty day complication rates increased with frailty but mFI-5 was not an independent risk factor (OR 0.51, 95% CI 0.22–1.18). Mean patient level SBS declined in both groups at 12 months (conservative −28%; surgical −8%), with a marginally significant interaction between treatment approach and frailty (p = 0.072). Symptom domain analysis showed significant improvement in visual and vestibulocochlear deficits irrespective of management, whereas conservative therapy was associated with poorer motor deficit recovery (p = 0.025). Conclusions Preoperative tumor volume and frailty jointly influence treatment approach, yet neither metric alone dictates management decision when considered together. Perioperative risk-reduction protocols may mitigate frailty-associated morbidity. While most neurologic symptoms improve within a year, frailer patients have attenuated symptomatic improvement, in addition to domain-specific differences.

Rommi Kashlan, Razan R. Faraj, Hithardhi Duggireddy et al. · 0 citations